CEO of Global Contract Research Organisation Broughton, Dr Paul Moran, will transition to the role of executive chairman.
Broughton, which is developing its position as a full-service solutions provider to the global life sciences sector, is continuing its commitment to delivering life-enhancing products to market.
Dr Moran will transition into the role of executive chairman in a bid to further grow Broughton’s global capacity, focusing on expanding its existing US team.
Co-founder and CSO, Chris Allen, will be appointed as CEO from 1 January 2022, and CRO, Dr Nveed Chaudhary, will take become chief scientific and regulatory officer.
Moran commented: “Since 2006, our focus has always been to help our clients succeed. With a passion for enhancing societal health and wellbeing, our expertise across harm reduction and next generation products now covers the broad life science industries of pharmaceuticals, nicotine-containing products and cannabinoids.
“This next phase of our expansion is part of our natural evolution to grow capacity and capabilities. I’ll continue to focus my energies on new markets and early initiatives.
“Chris has been with Broughton three weeks longer than me. He’s an outstanding leader, with great vision for the future growth of Broughton.’’
Allen added: “The recent changes to our management team reflect our continued commitment and ambition to become the most trusted integrated services provider in the world.
“Our additional investment plans into global operations will enable us to expand our services for clients across the nicotine, pharmaceutical and cannabinoids markets, always with a focus to help clients deliver life-enhancing products to market.
“I am delighted to take over the CEO role at Broughton. Harm reduction is our guiding principle. We’ve set ambitious targets to deliver marketing authorisations/orders across global markets for our clients.
“We have over 150 talented individuals across the life sciences team, with a healthy onboarding programme in 2022 for continued growth, that puts us in a strong position to progress on our mission”
[activecampaign form=31]
